Celgene Corp (CELG) 142.77 $CELG
Could Celgene Beat the Biotech Slide?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
Last Thursday, Celgene 's first quarter earnings call left the market with mixed emotions. Adjusted earnings per share of $1.67 beat estimates by just $0.02. Revenue grew 18.5% on year to $1.73 billion, $40 million less than the Street was...
Final Glance: Biotechnology companies
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Apr 28, 1:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Early Glance: Biotechnology companies
AP - Mon Apr 28, 9:56AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Tweet of the Week: Drugmakers Can't Get a Second Drug Approved
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
This week's tweet of the week comes from Frank David, who points out a fact he learned in an article by Matthew Herper: Over half of companies that got a drug approved by the FDA from 1950 to 2011 did so only once. In the following video, senior...
Will This Analyst Upgrade Help Celgene (CELG) Stock Today?
at The Street - Fri Apr 25, 8:33AM CDT
Piper Jaffray upgraded Celgene (CELG) to "overweight" from "neutral" and set a $170 price target. The firm cited valuation, as the stock has lagged over the past couple of months.
Celgene Corporation to Present at Investor Conferences in May
Business Wire - Fri Apr 25, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at four upcoming investor conferences in the month of May. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1613-100free.
Upgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Fri Apr 25, 6:59AM CDT
Celgene (NASDAQ:CELG) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $141.25 on volume of 4.4 million shares, above average daily volume of 4.3 million. Potential upside of 37.1% exists for Celgene, based on a current level of $141.25 and analysts' average consensus price target of $193.60. Celgene shares should first meet resistance at the 50-day moving average (MA) of $150.91 and find additional resistance at the 200-day MA of $152.22.
'Mad Money' Lightning Round: United Rentals Is Really Good
at The Street - Fri Apr 25, 5:00AM CDT
Cramer prefers HollyFrontier to CVR Refining and says wait a bit on GW Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Nerds Rule
at The Street - Thu Apr 24, 7:19PM CDT
Uncool companies left for dead last quarter are making a comeback, Cramer says.
Caterpillar and D.R. Horton are big market movers
AP - Thu Apr 24, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:27PM CDT
Product sales increased at Celgene (CELG) in the quarter.
Could Celgene Beat the Biotech Slide?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
Last Thursday, Celgene 's first quarter earnings call left the market with mixed emotions. Adjusted earnings per share of $1.67 beat estimates by just $0.02. Revenue grew 18.5% on year to $1.73 billion, $40 million less than the Street was...
Final Glance: Biotechnology companies
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Mon Apr 28, 1:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Early Glance: Biotechnology companies
AP - Mon Apr 28, 9:56AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Tweet of the Week: Drugmakers Can't Get a Second Drug Approved
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
This week's tweet of the week comes from Frank David, who points out a fact he learned in an article by Matthew Herper: Over half of companies that got a drug approved by the FDA from 1950 to 2011 did so only once. In the following video, senior...
Will This Analyst Upgrade Help Celgene (CELG) Stock Today?
at The Street - Fri Apr 25, 8:33AM CDT
Piper Jaffray upgraded Celgene (CELG) to "overweight" from "neutral" and set a $170 price target. The firm cited valuation, as the stock has lagged over the past couple of months.
Celgene Corporation to Present at Investor Conferences in May
Business Wire - Fri Apr 25, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at four upcoming investor conferences in the month of May. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1613-100free.
Upgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Fri Apr 25, 6:59AM CDT
Celgene (NASDAQ:CELG) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $141.25 on volume of 4.4 million shares, above average daily volume of 4.3 million. Potential upside of 37.1% exists for Celgene, based on a current level of $141.25 and analysts' average consensus price target of $193.60. Celgene shares should first meet resistance at the 50-day moving average (MA) of $150.91 and find additional resistance at the 200-day MA of $152.22.
'Mad Money' Lightning Round: United Rentals Is Really Good
at The Street - Fri Apr 25, 5:00AM CDT
Cramer prefers HollyFrontier to CVR Refining and says wait a bit on GW Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Nerds Rule
at The Street - Thu Apr 24, 7:19PM CDT
Uncool companies left for dead last quarter are making a comeback, Cramer says.
Caterpillar and D.R. Horton are big market movers
AP - Thu Apr 24, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:27PM CDT
Product sales increased at Celgene (CELG) in the quarter.
